Compare · ABCL vs NVO
ABCL vs NVO
Side-by-side comparison of AbCellera Biologics Inc. (ABCL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABCL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $170.83B, about 41.7x ABCL ($4.09B).
- Over the past year, ABCL is up 122.3% and NVO is down 32.7% - ABCL leads by 155.0 points.
- ABCL has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 21 for ABCL).
- Company
- AbCellera Biologics Inc.
- Novo Nordisk A/S
- Price
- $12.49-0.95%
- $38.15+0.25%
- Market cap
- $4.09B
- $170.83B
- 1M return
- +9.39%
- -10.35%
- 1Y return
- +122.28%
- -32.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 5
- 4
- Recent ratings
- 21
- 25
AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABCL
- UBS initiated coverage on AbCellera Biologics with a new price target
- AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
- AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
- Analyst initiated coverage on AbCellera Biologics with a new price target
- Goldman initiated coverage on AbCellera Biologics with a new price target
- AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
- Director Hayden Michael R bought $570,442 worth of shares (53,613 units at $10.64) (SEC Form 4)
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Montalbano John S. bought $110,300 worth of shares (10,000 units at $11.03), increasing direct ownership by 4% to 251,000 units (SEC Form 4)
- Chief Financial Officer Booth Andrew bought $383,904 worth of shares (37,200 units at $10.32), increasing direct ownership by 8% to 482,800 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank